Clinical Trials Logo

Filter by:
NCT ID: NCT04983355 Completed - Sleep Disorder Clinical Trials

Efficacy of the Marine Based Nutritional Supplement Peptidyss® on Sleep and Anxiety

Start date: July 19, 2021
Phase: N/A
Study type: Interventional

This interventional, double-blind, randomized, placebo-controlled pilot study aims to evaluate the effect of a dietary supplementation of a fish hydrolysate Peptidyss on sleep quality and anxiety.

NCT ID: NCT04979091 Completed - Covid19 Clinical Trials

Sex Hormone Dysregulations Are Associated With Critical Illness in COVID-19 Patients

HAM-SEX-C19
Start date: March 8, 2020
Phase:
Study type: Observational

Males develop more severe SARS-CoV-2 infection related disease outcome than females. Herein, sex hormones were repeatedly proposed to play an important role in Covid-19 pathophysiology and immunity. However, it is yet unclear whether sex hormones are associated with Covid-19 outcome in males and females. In this study, we analyzed sex hormones, cytokine and chemokine responses as well as performed a large profile analysis of 600 metabolites in critically-ill male and female Covid-19 patients in comparison to healthy controls and patients with coronary heart diseases as a prime Covid-19 comorbidity. We here show that dysregulated sex hormones, IFN-γ levels and unique metabolic signatures are associated with critical illness in Covid-19 patients. Both, male and female Covid-19 patients, present elevated estradiol levels which positively correlates with IFN-γ levels. Male Covid-19 patients additionally display severe testosterone and triglyceride deficiencies as compared to female patients and healthy controls. Our results suggest that male Covid-19 patients suffer from multiple metabolic disorders, which may lead to higher risk for fatal outcome. These findings will help to understand molecular pathways involved in Covid-19 pathophysiology.

NCT ID: NCT04976088 Completed - Inflammation Clinical Trials

Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs

Start date: May 25, 2018
Phase: Phase 3
Study type: Interventional

Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs.

NCT ID: NCT04976010 Completed - Clinical trials for Cardiovascular Diseases

Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease

Start date: July 17, 2021
Phase:
Study type: Observational

Chronic kidney disease (CKD) is associated with an increased cardiovascular mortality. In particular children with early-onset CKD have a lifelong increased risk to suffer from cardiovascular disease (CVD). Therefore, children with CKD deserve our attention. The immune system in children with CKD is disturbed, exhibiting pro-inflammatory features. Therefore, we aim to learn more about the characteristics of the immune system in early-onset CKD. In this project PBMC of pediatric CKD patients and age-matched healthy controls will be analysed and compared using CITE-Seq as a multimodal scRNAseq phenotyping method. All patients will be clinically characterized to integrate cardiovascular and immunological data.

NCT ID: NCT04974983 Completed - Glioblastoma Clinical Trials

Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

Start date: September 1, 2017
Phase:
Study type: Observational

This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.

NCT ID: NCT04972617 Completed - Critical Illness Clinical Trials

Characterization of the Efficacy of Furosemide Depending on Albumin Function

Start date: May 17, 2022
Phase:
Study type: Observational

During this prospective, uncontrolled and non-interventional observational study, the influence of albumin function on the efficacy of furosemide will be investigated. The aim of the study is to provide information on the efficacy of furosemide depending on albumin function.

NCT ID: NCT04972266 Completed - Clinical trials for Hemodynamic Monitoring

The EU Hyprotect Registry

Start date: September 28, 2021
Phase:
Study type: Observational [Patient Registry]

European, multicenter, prospective, observational registry in patients undergoing elective major non-cardiac surgery

NCT ID: NCT04971876 Completed - Clinical trials for Midface Volume Deficit

Evaluation of the Safety and Performance of an Injectable Hyaluronic Acid Filler

Start date: October 27, 2020
Phase: N/A
Study type: Interventional

Evaluation of the safety and performance of the investigational device in its three concentrations for cheek and lips augmentation and correction of the nasolabial folds, assuming that the performance of the product will be demonstrated based on the responder rates observed compared to baseline.

NCT ID: NCT04971746 Completed - Healthy Clinical Trials

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Start date: July 19, 2021
Phase: Phase 1
Study type: Interventional

The main aim of this study is to investigate the possible effect of GLPG4716 on the pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety and tolerability of GLPG4716 alone or administered simultaneously with pirfenidone or nintedanib.

NCT ID: NCT04970355 Completed - Cluster Headache Clinical Trials

Efficacy of Erenumab in Chronic Cluster Headache

CHERUB01
Start date: December 2, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of erenumab in participants with chronic cluster headache.